Cerevel Therapeutics Holdings, Inc. CERE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

22/100

0/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cerevel Therapeutics Holdings, Inc. (CERE) .

Criteria proven by this page:

VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($33.50, 25.5%).
Analyst consensus target $33.50 (-25.5% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 21/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

22/100

SG Score

View full scorecard →

✗

VALUE

10/100

Price-to-Earnings & upside

Proven by this page

✗

FUTURE

16/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

40/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — CERE

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-2.67

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

Analyst Target$33.50 (-25.5%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2012	$-2.07	$5.37M	$-29.41M	-547.6%
2013	$-2.28	$5.24M	$-32.51M	-620.1%
2014	$-0.81	$2.4M	$-29.32M	-1219.7%
2015	$-4.57	$2.72M	$-28.16M	-1035.1%
2018	$-164.93	$0.00	$-463.64M	-
2019	$-1.01	$0.00	$-128.39M	-
2020	$-2.07	$0.00	$-152.14M	-
2021	$-1.63	$0.00	$-222.45M	-
2022	$-2.32	$0.00	$-351.51M	-
2023	$-2.67	$0.00	$-432.84M	-